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The receptor activator of nuclear factor-κB (RANK) and its ligand, RANKL has 
have been implicated as an important link between breast cancer and metastasis to bone 
because of their ability to activate intracellular signal cascades leading to altered cancer 
cell behaviour and bone breakdown.  The JAK/STAT5a cell signaling pathway is also 
crucial to breast biology and is involved in transcriptional regulation of many genes.  The 
objective of this study is to determine if RANKL mRNA expression is regulated through 
the JAK/STAT5a pathway by stimulating human breast cancer cell lines, MCF-7 and 
MDA-MB-231, with prolactin (PRL), epidermal growth factor (EGF) and heregulin-
beta1 (HRG-β1), all known to activate STAT5a and play a role in breast cancer 
progression.  This study shows that RANKL expression is upregulated by PRL, EGF and 
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ATCC – American Type Culture Collection 
BSA – bovine serum albumin 
DMSO – dimethyl sulfoxide  
ECL – enhanced chemiluminesent 
EDTA - ethylenediaminetetraacetic acid 
EGF – epidermal growth factor  
EGFR – epidermal growth factor receptor 
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ER – estrogen receptor 
FBS – fetal bovine serum  
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GAS – gamma interferon activation site 
GRB-2 – growth factor receptor-bound protein 2 
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IGF-2 – insulin-like growth factor-2 
IGFR – insulin-like growth factor receptor  
IL – inerleukin 
iNOS – inducible nitrous oxide synthase  
JAK2 – Janus-activated kinase 2 
MAPK – mitogen-actived protein kinase 
MGF – mammary gland factor  
MMP-9 – matrix metalloproteinase 9 
NDF – neu differentiation factor  
NF-κB – nuclear factor kappa B 
NRG – neuregulin  
ODF – osteoclast differentiation factor  
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PLC-γ - phospholipase C gamma 
PR – progesterone receptor  
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PRL – prolactin 
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RANK – receptor activator of nuclear factor kappa B 
RANKL – receptor activator of nuclear factor kappa B ligand 
SDS – sodium dodecyl sulfate 
SH2 – src homology 2 
SOS – son of sevenless  
STAT – signal transducer and activator of transcription 
TGF-α – transforming growth factor alpha 
TNF – tumor necrosis factor  
TNFR – tumor necrosis factor receptor 
TRAF – tumor necrosis factor receptor-associated factors  
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 1 - Introduction 
 
 
1.1 – Receptor Activator of Nuclear Factor-κB and Its Ligand  
 
1.1.1 – RANK 
 
 The Receptor Activator of Nuclear Factor κB (RANK - also known as tumor 
necrosis factor-related activation-induced cytokine (TRANCE) and osteoclast 
differentiation factor (ODF)) is a member of the tumor necrosis factor (TNF) cell surface 
receptor superfamily.  This receptor is involved in the activation of the transcription 
factor Nuclear Factor Kappa-B (NF- κB), and thus controls transcription of its target 
genes via an intracellular cascade of signals (Wei et al, 2001). 
 The RANK protein is a transmembrane receptor that consists of 383 amino acids 
and contains a highly conserved cysteine extracellular domain and a relatively long 
intracellular domain unique to other TNF receptors (Darnay et al, 1998).   RANK mRNA 
is highly expressed in bone marrow derived osteoclasts and mature osteoclast progenitors 
including bone cells.  RANK protein is typically expressed on cells of the 
macrophage/monocytic lineage, T cells, B cells, dentritic cells, and fibroblasts (Anderson 
et al, 1997; Hsu et al, 1999).  Studies prove that RANK is expressed in mammary 
epithelial cells, but not stromal cells (Srivastava et al, 2003) 
 
1.1.2 – RANKL 
 
 The receptor activator of nuclear factor-κB ligand (RANKL) binds the RANK 




chromosome 13q14 (Anderson et al, 1997) and spans approximately 36 kb of genomic 
DNA and comprises six exons.  The gene also exists as two other isoforms: hRANKL2 
and hRANKL3.  These isoforms are translated at the downstream in-frame start codons 
(Suzuki et al, 2004) and both lack the N-terminus intracellular domain.  The hRANKL3 
isoform also lacks a transmembrane domain, resulting in a soluble form of RANKL.  All 
three isoforms contain identical C-terminal extracellular domains. 
 The RANKL protein is highly conserved with human and mouse sharing 87% 
homology (Lacey et al, 1998).  It also shares 30% homology to TNF-related apoptosis –
inducing ligand (TRAIL) (Lacey et al, 1998) and 20% homology to Fas ligand (Anderson 
et al, 1997).  The RANKL protein also exists in three forms: a 45 kDa membrane-
associated protein, a 31 kDa soluble protein by proteolytic cleavage or as a 39.5 kDa 
soluble protein following expression of the hRANKL3 isoform (Ikeda et al, 2001).  
RANKL mRNA is expressed in fewer tissues, but at high levels in bone and bone 
marrow, with some expression in thymus, spleen, fetal liver, and Peyer’s patches 
(Simonet et al, 1997).  Its expression is induced in breast epithelial cells only during 
pregnancy and lactation (Fata et al, 2000). 
 
1.1.3 – The NF-κB Signaling Pathway 
 
NF-κB is a transcriptional regulator present in mammalian cells, where it 
regulates genes involved in apoptosis, cell cycle control, immune responses, and many 
other cell events (Dolcet et al, 2005).  This regulator is activated by two separate 
pathways, the canonical pathway and alternative pathway, each of which leads to nuclear 




The RANK-RANKL pair exerts their effects through the alternative signal 
transduction pathway that causes activation of NF-κB (Cao et al, 2001).  Although the 
exact mechanism of this transduction pathway is not fully elucidated, there has been 
considerable progress in unfolding this pathway, especially in osteoclasts and osteoclast 
precursor cells.  RANKL, either membrane-bound or soluble forms, bind to the RANK 
receptor ultimately causing activation of the catalytic subunit IKKα (Cao et al, 2001).  
When RANKL binds with its receptor, the RANK receptor interacts with subunits 
referred to as TNF-receptor associated factors (TRAFs).  TRAF molecules are 
cytoplasmic adaptor proteins that mediate the signaling events for specific members of 
the TNFR family.  There are currently six known TRAF proteins all containing an N-
terminal zinc RING finger, multiple zinc fingers, and C-terminal TRAF-N and TRAF-C 
domains.  After ligand binding, RANK can interact with a variety of TRAF proteins (1, 2, 
3, 5 and 6) (Hsu et al, 1999), however TRAF6 appears to be the most critical for RANK 
signaling (Mizukami et al, 2002). 
 Recent studies have shown activation of NF-κB to be linked to several types of 
cancer (Karin et al, 2002).  In many tumour cells, genes involved in NF- κB activation 
are deregulated, causing it to be constantly activated (Dolcet et al, 2005).  NF- κB is 
believed to play many roles in normal cell cycle progression, including promoting the 
expression of cyclins, important cell cycle machinery.  NF- κB promotes expression of 
cyclins D1 (Guttridge et al, 1999), D2 (Hinz et al, 1999), D3 (Hinz et al, 2001), and E 
(Hsia et al, 2002), and c-myc (Duyao et al, 1992).  In particular, cyclin D1 expression has 





1.2 - Functions of the RANK/RANKL Pathway 
 
 
1.2.1 – Role in Bone Remodeling and Bone Disease 
 
 The RANK/RANKL pathway has emerged as an important pathway in bone 
remodeling.  Bone is constantly degraded and reformed, at a consistent rate through the 
actions of osteoblasts and osteoclasts.  These two cell types have opposite functions in 
bone remodeling and skeletal homeostasis.  Osteoblasts originate from mesenchymal 
stem cells and differentiate into mature, matrix-secreting osteoblasts.  Osteoblasts are 
responsible for the rebuilding of bone by secreting extracellular matrix proteins, which 
over time become mineralized to form functional bone.  Osteoclasts are multinucleated 
giant cells involved in degrading bone matrix and originate from hematopietic cells.  
Degradation is accomplished by the osteoclast attaching to the surface of the cell and 
creating a sealed off environment in to which it will secrete proteolytic enzymes, 
removing osteoid and exposing the bone mineral.  The osteoclast then releases H+ into the 
space, creating pores in the bone. 
 The cycle of bone remodeling is a tightly regulated process, involving several 
stages.  The process of osteoclast maturation and bone resorption is tightly regulated by 
three main factors: the RANK receptor, its ligand, RANKL, and a decoy receptor 
osteoprotegerin (OPG).  RANK is expressed by most multinucleated osteoclasts (Burgess 
et al, 1999), and RANKL mRNA is expressed in high levels by bone osteoblasts 
(Simonet et al, 1997).  RANKL binds specifically to the RANK receptor on osteoclast or 
osteoclast precursor cells and activation of this pathway by RANKL binding results in 
osteoclast maturation (Malywankar et al, 2000; Lacey et al, 1998), increased osteoclast 




Studies have specifically shown RANKL to affect bone resorption by inducing 
osteoclasts to undergo a rearrangement of actin to form rings and perform multiple cycles 
of bone resorption (Burgess et al, 1999).  See Figure 1. 
 OPG acts as a decoy receptor, decreasing the effects of RANK-RANKL signaling 
by competitively binding to RANKL.  OPG is a RANK homolog and functions by 
binding to RANKL on osteoblast/stromal cells and thus inhibiting RANK-RANKL 
interaction and osteoclast activity (Figure 1).  OPG mRNA is expressed in a large number 
of tissues including lung, kidney, heart, liver, stomach, intestine, brain and spinal cord, 
thyroid gland, and bone (Simonet et al, 1997; Yasuda et al, 1998). 
 Knockout studies in mice have been the major contributor to knowledge about the 
functions of the RANK/RANKL pathway in bone.  Studies in which mice are rendered 
null for the rankl gene, mice have been shown to suffer osteopetrosis, stunted growth and 
a defect in tooth eruption due to failed osteoclast development (Simonet et al, 1997; Kong 
et al, 1999a).  RANKL -/- osteoblasts were not able to support normal osteoclastogenesis, 
and therefore mice showed decreased osteoclast production and severely impaired bone 
remodeling (Kong et al, 1999a). 
 
 
Figure 1: The activation of osteoclast cells through the binding of RANKL to the RANK 





1.2.2 – Role in Immunology 
 
 Along with being expressed in bone cells, RANK and RANKL are also expressed 
in activated T cells, B cells, and dendritic cells (Anderson et al, 1997; Kong et al, 1999b).  
This information led to the discovery of the role of this pathway in survival of dendritic 
cells, dendritic-T-cell interactions (Page and Miossec, 2005), organogenesis and 
lymphocyte differentiation (Wong et al, 1999).  A study by Kong et al (1999b), found 
that co-culturing activated CD4+ T cells and bone marrow cells induced 
osteoclastogenesis, which could be blocked by the addition of OPG.  Soluble RANKL 
produced by T lymphocytes is able to induce functional osteoclasts (Kong et al, 1999b).  
This indicates that there is a clear link between activated T lymphocytes and 
osteoclastogenesis, thus linking bone destruction and immune disorders, such as 
rheumatoid arthritis (Kong et al, 1999b).  RANKL knock-out mice are immuno-
compromised and lack Peyer’s patches. 
 
1.2.3 – Role in Lobular-Alveolar Development  
 
 The human breast undergoes many stages of development, growth and 
differentiation.  The mammary gland is composed of epithelial cells forming a branched 
ductal system during puberty and a lobuloalveolar compartment that develops during 
pregnancy (Henninghausen and Robinson, 2001).  The ducts constantly branch into 
smaller and smaller ductules, eventually terminating in lobules.  These lobules consist of 
alveoli, which in turn consist of secretory epithelial cells that undergo functional 
differentiation (Henninghausen and Robinson, 2001).  This complete structure allows for 




A new role for RANK/RANKL pathway emerged from the study of mice 
rendered null for RANK and RANKL through genetic ablation.  Along with defects in 
osteoclast development and immune dysfunction, mice also lacked lobulo-alveolar 
structures during pregnancy, eliminating lactation (Simonet et al, 1997; Fata et al, 2000).  
Loss of these structures was due to lack of proliferation and differentiation of the alveolar 
buds into functional mammary gland, but mice actually exhibited normal mammary 
development at earlier stages, such as ductal side-branching and formation of the initial 
alveolar buds (Fata et al, 2000).  Fata et al (2000) found that RANKL induced lobulo-
alveolar development in mice by stimulating proliferation of alveolar bud epithelia.  
Delivery of RANKL into the mammary tissue of pregnant RANKL-/- mice restored the 
lobulo-alveolar differentiation and milk production (Fata et al, 2000).   
The RANK-RANKL pathway was the first system identified that is connected to 
both breast development and bone destruction, providing clues to the prevalence of 
osteoporosis in women and the frequent occurrence of metastasis of breast cancer to 
bone.  Thus, the RANK/RANKL system became the first molecular link between breast 
and bone.   
 
1.2.4 – Role in Breast Cancer Progression and Metastasis  
 
 RANKL has recently been studied for its role in breast cancer progression.  Not 
only is RANKL required for the formation of lobulo-alveolar structures in the breast 
during pregnancy, but it is also been shown to cause an increase in proliferation and 
decrease in apoptosis of mammary epithelial cells when over-expressed in transgenic 




cancer cell lines (Jones et al, 2006) and other carcinomas (Mikami et al, 2009) with 
recombinant RANKL protein stimulation and also report that blockade of 
RANK/RANKL signaling slows metastasis of cancer to bone (Canon et al, 2008). 
Metastasis to bone is the most common outcome of advanced breast cancer, and is 
what most often causes lethality.  In fact, approximately 80% of patients with advanced 
breast cancer suffer from bone metastases (Lau et al, 2009).  For this reason, researchers 
have been attempting to understand the mechanism of preferential bone metastases.  After 
understanding the role of the RANK/RANKL system in osteolysis and osteoclast 
maturation and its connection to female hormones and involvement in proliferation of 
breast tissue, it is clear that this system exposes an important link between breast and 
bone. 
 It has been shown that RANKL plays an important role in the aspects of breast 
cancer progression by affecting proliferation, apoptosis and motility; but what causes the 
large amount of breast metastasis to bone?  Metastasis requires several important steps, in 
order for a tumor to leave its primary site and sustain in a secondary location in the body.  
The metastatic process begins with proliferation of the primary tumor and invasion 
through adjacent tissues and basement membranes.  Once the tumor invades blood 
vessels or lymphatic channels, tumor cells can detach from the primary tumor site and 
travel through the blood or lymphatic fluid to a secondary organ.  Upon arrival at the 
secondary tissue, the tumor extravasates into the surrounding tissue and continues to 
proliferate.  All of these steps are highly regulated by the expression or inhibition of 




The outcome of bone metastases depends on the microenvironment and the 
interactions of the tumor and host cells.  Stephen Paget (1889) was the first to introduce 
the concept of the ‘seed and soil’ theory, which describes the interaction of breast tumor 
cells with bone.  The bone microenvironment is a very fertile “soil” for seeding 
circulating cancer cells.  Bone turnover provides an environment rich in factors for cancer 
growth.  As mentioned previously, RANKL is a regulator in osteoclastogenesis and 
ultimately bone degradation, which releases cytokines and growth factors.  In breast 
cancer, bone metastases are predominately osteolytic, meaning bone destruction is caused 
by osteoclast stimulation and not by the direct effects of the cancer cells on bone (Yoneda 
et al, 1994).  The mechanism of osteolytic metastasis has not been fully elucidated, but 
there are many factors that are slowly being unraveled by researchers.  In metatastic 
human breast cancer, parathyroid hormone-related protein (PTHrP) has so far been 
shown to be the main player.  PTHrP is a key mediator for osteoclast activation and is 
expressed in human osteolytic breast cancer cells in vivo (Bryden et al, 2002).  Release of 
PTHrP and interleukins (IL) 1, 6, and 11 by tumor cells stimulate production of RANKL 
and decrease OPG in stromal and osteoblast cells (Thomas et al, 1999).  Conversely, 
expression of these proteins did not cause an upregulation of RANKL in breast cancer 
cells themselves, indicating that the tumor cells have an indirect effect on osteoclast 
activation (Thomas et al, 1999).  However, some studies do show that RANKL 
expression in breast cancer cells is upregulated by co-culture with osteoblasts (Schubert 
et al, 2008).  An increase of RANKL in osteoblast and stromal cells will ultimately lead 
to an increase in bone resorption and the formation of osteolytic lesions.  Bone resorption 




completing a feedback loop.  RANKL can also stimulate angiogenesis (Kim et al, 2003) 
and endothelial cell survival (Kim et al, 2002), which suggests a role in supporting 
vascularization in bone metastases. 
 
1.3 – Signal Transducer and Activator of Transcription Pathway 
 
 
1.3.1 – STAT proteins 
 
 Signal transducers and activators of transcription (STATs) are transcriptional 
regulators involved in many biological processes, including cell growth, differentiation 
and survival.  Seven STAT proteins have been identified: STAT1, STAT2, STAT3, 
STAT4, STAT5a, STAT5b, and STAT6 (Copeland et al, 1995).  Each of the STAT 
proteins contains several conserved domains, which tend to be present in transcription 
factors.  These domains include heptad leucine repeats, a helix-turn-helix motif and Src 
Homology (SH)- 2 and -3 domains.  The SH2 domain is involved in the specific binding 
to a sequence motif flanking a tyrosine phosphorylated residue, while the SH3 domain is 
likely involved in targeting of signaling components to specific subcellular locations. 
These STAT proteins are activated through signal transduction pathways and 
become phosphorylated on tyrosine residues.  After the protein is activated by 
phosphorylation, it forms homomeric and heteromeric dimers by an SH2 phosphotyrosine 
interaction, and then enters the nucleus where it will regulate transcription. 
 
1.3.2 – STAT5a Pathway in Mammary Gland Development 
 
 The STAT5 protein was first discovered in the mouse mammary gland and termed 




this protein shared significant sequence homology with the STAT family and was later 
termed “STAT5” (Gouilleux et al, 1994; Wakao et al, 1994).  Another isoform of the 
STAT5 protein was discovered in the mammary gland shortly following and was 
subsequently termed “STAT5b”, where the original STAT5 protein was termed 
“STAT5a”.  These two compounds are highly similar, sharing 96% homology (Liu et al, 
1995).  Stat5a transduces its signal through interaction with Janus-activated kinase 
(JAK)-2.  Binding of a ligand to the receptor allows for receptor dimerization bringing 
two JAK2 molecules in close proximity and allowing them to phosphorylate tyrosine 
residues on themselves and the receptor.  Other STAT5a/b proteins are able to recognize 
these tyrosine motifs through their SH2 domains and are recruited to docking sites.  This 
causes rapid phosphorylation of a conserved tyrosine residue on the C-terminus of Stat5a 
by JAK2.  Phosphorylation of Tyr694 on the Stat5a molecule causes it to be active and 
homo- or heterodimerize and translocate to the nucleus. 
 Stat5a is involved in mammary gland development, specifically in pregnancy 
during lactation.  Phosphorylation of Stat5a and Stat5b is very low in the mammary tissue 
of virgin mice and during early pregnancy, however levels rise drastically after day 14 of 
pregnancy in mice (Lui et al, 1996), indicating that Stat5a phosphorylation may be a 
critical step in the terminal differentiation of mammary secretory epithelium.  Stat5a null 
mice exhibit decreased lobuloalveolar development and are unable to lactate after their 
pregnancy (Liu et al, 1997).   
 The importance of STAT5a in the development of secretory lobuloalveolar 
structures relies mainly on its ability to regulate gene expression.  Most notably, STAT5a 




Along with milk proteins, STAT5a is thought to regulate genes involved in proliferation 
and cell cycle progression; however these mechanisms are far less recognized.  Cyclin D1 
is an important cell cycle regulator that is thought to be regulated by STAT5a, as mice 
deficient in cyclin D1 exhibit similar phenotypes to STAT5a knock-out mice (Fantl et al, 
1995; Sicinski et al, 1995).  It is hypothesized that cyclin D1 is either upregulated directly 
by STAT5a through activation of its promoter (Brockman and Schuler, 2005) or 
indirectly through the activation of insulin-like growth factor-2 (IGF-2) (Brisken et al, 
2002).  Thus, STAT5a plays a major role in proliferation and development of the breast 
during pregnancy.  
 
 
1.3.4 –STAT5a Pathway in Breast Cancer 
 
 Although the JAK2-STAT5a pathway is involved in normal development of the 
mammary gland and breast, it is also being investigated for its role in cancer progression.  
STAT5a is involved in normal cellular processes that involve accelerated cell 
proliferation (Iavnilovitch et al, 2002) and inhibition of cell apoptosis (Cui et al, 2004), 
therefore it is possible that disruption of STAT5a regulation may be a cause of cancer 
progression and initiation.  This may happen through mutations enhancing the 
transactivation potential, altered activity of STAT5 regulators, or through expression of 
interacting proteins. 
Studies of STAT5a in cancer initiated in transgenic mice expressing TGF-α in 
their mammary glands, show development of mammary hyperplasia and tumors, in which 
the onset could be delayed by the inactivation of STAT5a.  Mice with decreased levels of 




smaller in size (Ren et al, 2002).  This was the first bit of evidence that linked STAT5a to 
mammary-tumor initiation and progression.   
In cases of human breast cancer, studies have shown conflicting results when it 
comes to the involvement of STAT5a in initiation, progression, and metastasis.  A study 
completed by Cotarla et al (2004), indicated that STAT5a was tyrosine-phosphorylated 
and nuclear localized in 76% of invasive breast adenocarcinomas examined.  This study 
also observed a positive correlation between tumor differentiation and active STAT5a.  
Conversely, in a larger study with more than 1100 breast cancer specimens, active 
STAT5a was associated with a favorable prognosis (Nevalainen et al, 2004).  Active 
STAT5a was associated with an increased overall patient survival, and loss of activated 
STAT5a in primary tumors of patients with lymph node-negative breast cancer was 
associated with an increased risk of death from breast cancer (Nevalainen et al, 2004).  
Other studies confirm that STAT5 protein levels in estrogen receptor (ER)-positive breast 
cancer were correlated with favorable prognosis and improved response to antiestrogenic 
therapy (Yamashita et al, 2006).  Also, levels of active STAT5a were generally reduced 
in breast cancers when compared to healthy luminal breast epithelial cells (Bratthauer et 
al, 2006), however, these levels were retained in more differentiated, secretory breast 
cancer (Strauss et al, 2006).  More studies will need to be conducted in order to determine 
how STAT5 is implicated in breast cancer, although present evidence clearly shows that 
it plays an important role. 
 
1.3.5 – Regulation of RANKL Transcription by STAT 
 
RANKL transcription is regulated by STAT proteins, due to their ability to bind 




promoter region of the rankl gene (Standke et al, 1994; Wakao et al, 1994).  RANKL has 
been shown to be upregulated in mouse mammary epithelial cells through the induction 
of the JAK2-STAT5a pathway by prolactin (Srivastava et al, 2003).  However, regulation 
of RANK/RANKL has not been determined in human breast epithelial or breast cancer 
cells. 
 
1.4 – Prolactin 
 
1.4.1 - Prolactin and the Prolactin Receptor 
 
 Prolactin (PRL) is a polypeptide hormone primarily synthesized and secreted by 
lactotrope cells in the anterior pituitary gland, although it is also produced in other 
glands, including the breast, deciduas, and parts of the central nervous system and 
immune system.  The prolactin receptor (PRLR) belongs to the cytokine hematopoietic 
family of receptors and contains three specific domains: an extracellular ligand-binding 
domain, a hydrophobic transmembrane domain, and an intracellular cytoplasmic domain.  
The cytoplasmic domain includes two conserved motifs: box 1, a proline rich domain 
involved in protein-protein interactions, and box 2, which contains no known consensus 
sequence, but plays a crucial role in signal transduction.   
There are three forms of PRLRs present: long, intermediate and short, which 
differ in the length of their cytoplasmic domains.  The intermediate form results from a 
deletion mutation of the long form, and lack 198 amino acids in its cytoplasmic region.  
The long and intermediate forms have both been recognized in mammary and human 





1.4.2 – Induction of JAK2-STAT5a pathway by prolactin 
 
The most well known activator of the JAK2-STAT5a pathway in mammary gland 
development is PRL.  Binding of PRL to its receptor initiates homodimerization of the 
receptor, followed by phosphorylation of JAK2 (Rui et al, 1994).  JAK2 then 
phosphorylates the PRLR and the STAT protein docks at the tyrosine residues of the 
PRLR that were phosphorylated.  The activated JAK2 then causes phosphorylation of the 
tyrosine residue - 694 (Tyr-694) on the STAT5a protein (Gouilleux et al, 1994).  
Phosphorylated STAT5a forms homo and hetero-dimers and is transported to the nucleus, 
where it regulates the transcription of many genes.  Figure 2 illustrates this. 
PRL has been shown to induce STAT5a activation in many cell lines, including 
human breast cancer cells.  Canbay et al (1997) demonstrated that when T47-C breast 
carcinoma cells were stimulated with PRL, JAK2 was phosphorylated in a time- and 
dose-dependent manner.  The same study showed a similar effect in MCF-7, ZR-75-1 and 
MDA-MB-231 cells, but to a lesser extent.  In breast cancer cell lines, JAK2 
phosphorylation by PRL has caused ErbB2 phosphorylation, stimulating the Ras-mitogen 
activated protein kinase (MAPK) pathway, leading to unrestricted proliferation 







Figure 2: The induction of the JAK2-STAT5a pathway by prolactin and its proposed 
effect on the transcriptional regulation of RANKL. 
 
 
1.4.3 - Prolactin in Breast Development  
 
 It has already been stated that STAT5a plays an important role in breast 
development, and that PRL activates the JAK2-STAT5a pathway.  Therefore, the main 
role of PRL is the development of alveolar buds in the breast during pregnancy, and the 
stimulation of postpartum lactogenesis by driving expression of milk producing proteins, 
such as whey acidic protein (WAP) (Andres et al, 1987) and β-lactoglobulin (Whitelaw, 
1995).   
 Evidence of the role of PRL in mammary gland development and lactation come 
largely from studies with organ cultures and cell lines.  Many in vivo studies involve the 
generation of mice from which the genes encoding the PRLR, Stat5a and Stat5b have 
been inactivated.  In these studies, PRLR -/- mice displayed normal ductal elongation 
during puberty, however secondary side-branching does not occur and ducts become 




expressing only one PRLR allele failed to lactate after their first pregnancy due to 
reduced mammary gland development (Ormandy et al, 1997).  This indicates that 
epithelial cell proliferation during pregnancy is dependent on sufficient PRLR, which 
cannot be obtained with only one allele.   In PRLR -/- mice epithelium is unable to 
proliferate to form lobuloalveoli (Brisken et al, 1999), similar to the phenotype seen in 
STAT5a -/- mutants.  PRLR -/- mothers fail to lactate and mammary glands show 
formation of lobules, but they are unable to form an open lumen or secrete milk 
(Ormandy et al, 1997; Brisken et al, 1999).  
PRL also drives expression of RANKL through the JAK2-Stat5a pathway in 
mammary epithelial cells (Srivastava et al, 2003).  Using dominant negative mutants for 
JAK2 and STAT5a, these researchers discovered that there is a clear link between the 
PRL response and STAT5a activation.  This study found gamma interferon activation site 
(GAS) elements in the promoter region of the RANKL gene, which they believe is how 
the PRL-response was conferred (Srivastava et al, 2003).  The finding of this paper leads 
to the conclusion that PRL activates the JAK2-STAT5a pathway to activate RANKL 
expression in mammary epithelial cells.  Activation of the RANK/RANKL pathway 
through STAT5a therefore initiates the formation of lobuloalveolar structures in lactating 
mice, supported by similar phenotypes seen by STAT5a -/- and RANKL -/- mutants. 
 
1.4.4 - Prolactin and Breast Cancer 
 
 Over time many studies have found a positive link between PRL and mammary 
gland carcinogenesis in mice.  In vivo studies in transgenic and knockout mice are 




PRL from the metallothionein promoter develop mammary tumors (Wennbo et al, 1997) 
and normal mice that are administered ovine PRL daily show an increase in the incidence 
of mammary tumorgenesis (Boot et al, 1962).  A study by Yanai and Nagasawa (1972) 
shows that mammary tumors secrete PRL and that administration of a drug shown to 
reduce PRL causes a drastic reduction in the incidence of mammary tumors.   PRL is 
produced by transgenic mammary epithelial tumor cells in culture and is able to promote 
lobuloalveolar development, indicating that PRL may be acting in an autocrine manner to 
promote proliferation and carcinogenesis (Wennbo et al, 1997). 
In humans, the role of PRL in breast cancer is far less established and relies 
mostly on correlation.  PRLR expression has been found in over 70% of breast biopsy 
samples by specific biniding assays (Codegone et al, 1981; Peyrat et al, 1981; Bonneterre 
et al, 1982).  In breast cancer surgical samples, cancerous tissues contained significantly 
more mRNA for the PRLR than did adjacent, noninvolved tissue from the same patient 
(Clevenger et al, 1995).  Serum prolactin is detected in 60-85% of breast cancer biopsies 
(Purnell et al, 1982; Agarwal et al, 1989), however there is no clear correlation between 
levels of PRL and PRLR content or the etiology or prognosis of the disease (DePlacido et 
al, 1990).  Holtkamp et al. (1984) reported elevated levels of PRL in 44% of patients with 
metastatic breast cancer and several other studies have claimed that basal serum levels 
were higher in women who were at risk of familial breast cancer (Love et al, 1991).  Most 
significantly, a study by Vonderhaar (1998) shows that PRL is synthesized by MCF-7 
and T47Dco human breast cancer cells and acts in an autocrine manner to stimulate cell 




through the secretion of PRL and that PRL can be directly correlated to the progression of 
human breast cancer. 
 
 
1.5 – Epidermal Growth Factor  
 
1.5.1 – Epidermal Growth Factor and Family Receptors 
 
 The epidermal growth factor receptor family, also known as the ErbB protein 
family, consists of four structurally related receptor tyrosine kinases: erbB-1 (also known 
as EGFR), erbB-2 (also known as Human Epidermal growth factor Receptor 2 (HER2)), 
erbB-3 (HER3), erbB4 (HER4).  Epidermal growth factor (EGF) binds to EGFR, 
however this receptor has many other functional ligands including transforming growth 
factor (TGF)-α (Garrett et al, 2002).  EGF only binds to EGFR, but the other erbB 
receptors bind a variety of other growth factor ligands that initiate tyrosine kinase 
cascades. 
 
1.5.2 – EGF and Signal Transduction  
 
 Along with PRL, epidermal growth factor (EGF) can also activate STATs to elicit 
transcriptional regulation of many genes.  Binding of EGF or other ligands to the EGFR 
can cause STAT proteins to bind to the receptor, becoming activated through the SH2 
domain (Silvennoinen et al, 1993).   EGFR can phosphorylate STAT1, STAT3 and 
STAT5 proteins on Y701, Y705, and Y694 residues respectively (Rane and Reddy, 
2002).  Although STATs can bind directly to the EGFR, JAKs are required to provide 




translocate to the nucleus where they can bind to a variety of target genes or other 
regulatory proteins c-fos and c-jun, which regulate transcription (Leeman et al, 2006). 
 Not only does the EGFR mediate signals directly through STAT proteins, it can 
also indirectly activate STAT proteins through alternative pathways.  For instance, EGF 
is involved in the signaling through phospholipase C-γ (PLC-γ) (Wahl et al, 1990) and 
phosphatidylinostol-3 kinase (PI3K) (Bjorge et al, 1990).  EGF can also activate the 
MAPK pathway, which regulates cell proliferation and survival (Scaltriti and Baselga, 
2006).  In this pathway, growth factor receptor-bound protein 2 (GRB2) and son of 
sevenless (SOS) complex bind to EGFR and phosphorylate Ras (Scaltriti and Baselga, 
2006).  Binding of EGF to the EGFR can also cause nuclear translocation of the entire 
complex and direct transcriptional regulation of genes (Lin et al, 2001).  For instance, 
EGFR functions as a transcription co-factor that interacts with and activates the cyclin D1 
gene, a promoter of cell proliferation (Lin et al, 2001).  The inducible nitrous oxide 
synthase (iNOS) gene has recently been discovered as another target of EGFR signaling 
(Lo et al, 2005).   
 
1.5.3 – EGF and Mammary Gland Development 
 
Evidence found in the studies of mice suggest that it is signaling through EGFR 
and ErbB-2 that are responsible for ductal development of the pubescent gland, while 
signaling though ErbB-3 and ErbB-4 is important for alveolar morphogenesis and 
lactation.  In egfr-/- mutants, mice lack ductal development and show very few 
proliferating cells in the stroma or epithelial ducts, indicating EGF is involved in the 
ductal morphogenesis of the mammary gland (Wiensen et al, 1999).  These same mice 




since the mammary glands were still competent to respond to other hormonal signals 
(such as prolactin) to elicit a lactational phenotype (Wiensen et al, 1999).  EGF is 
expressed in virgin and pregnant mice, as well as 10-day lactating mice and is localized 
in the inner layers of the terminal end bud and in ductal cells of the mammary epithelium 
(Snedeker et al, 1991).  Studies have detected only EGFR and ErbB-2 receptors in the 
developing virgin gland, while all four ErbB receptors were expressed and maximally 
phosphorylated during pregnancy and lactation (Schroeder and Lee, 1998; Sebastian et al, 
1998).  
 
1.5.4 – EGF and Breast Cancer  
 
A clear tie lies between EGF and breast cancer, as it is also linked to STAT5a 
activation and has been shown to activate NF-κB, both of which are correlated to breast 
cancer progression.  The role of EGF in breast cancer first came to light when an 
experiment showed that overexpression of EGFR in cells in the continuous presence of 
EGF caused the cells to become transformed (Velu et al, 1987). 
In murine studies, a casual relationship is represented by the amount of nuclear 
accumulation of EGFR and cell proliferation and DNA synthesis (Marti et al, 1991; Marti 
et al, 1995; Lin et al, 2001).  Research shows that EGFR can regulate autocrine and 
paracrine growth signals in vitro (Ennis et al, 1989; Valverius et al, 1990).  
EGFR is overexpressed in many human cancers including breast, prostate, 
ovarian, liver, bladder, stomach, lung, colon, esophagus and larynx (Khazaie et al, 1993). 
In a study by Kondapaka (1997), EGF induced proliferation of metastatic and non-
metastatic breast cancer cells and induced expression of matrix metalloproteinase 9 




ability to hydrolyze a variety of extracellular matrix proteins.  Many studies on human 
isolated tissues have shown nuclear localized EGFR were correlated with a poor clinical 
outcome in breast cancer (Klijn et al, 1992; Seshadri et al, 1996). As mentioned, nuclear 
EGFR mediates transcriptional activation of the cyclin D1 gene, a positive regulator in 
cell proliferation (Lin et al, 2001), creating yet another positive link to breast cancer 
progression. 
 
1.6 – Heregulin Beta-1 
 
1.6.1 - Heregulin Family  
 
Heregulin (HRG), also known as neu differentiation factor (NDF), belongs to the 
Type I class neuregulin 1 (NRG1).  Neuregulins are a family of structurally related 
proteins that are actually a part of the EGF family and are involved in growth and 
differentiation of epithelial, glial and muscle cells in culture.  There are several forms of 
HRG: HRG-α, HRGβ1, HRGβ2, HRGβ3, and HRGγ.  HRGs actually contain an EGF-
domain, which shares homology with the EGF protein.  This domain is involved in HRG 
ligand binding to erbB3 and erbB4 receptors (Jones et al, 1998).  These receptors can 
form homo- or heterodimers that can mediate the STAT5a pathway, similar to EGFR. 
 
1.6.2 – Heregulin β-1 Signalling in Mammary Gland Development 
 
 HRG is an important factor in pathways involved in mammary gland development 
and its expression is highly regulated.  HRG-α is expressed in mammary mesenchyme 
adjacent to lobuloalveolar structures and is only expressed at the onset of pregnancy 




formation and to produce required milk proteins (Yang et al, 1995).  Similar to TNF-α, 
both HRG-α and HRG-β induce epithelial branching and differentiation into 
lobuloalveolar structures and stimulate the accumulation of luminal secretory products, 
such as beta-casein, an essential milk protein in vivo (Jones et al, 1996).  HRG-β1 acts 
through the STAT5 pathway, as it is known to bind to and activate erbB3 and erbB4 
receptors (Jones et al, 1998; Puricelli et al, 2002).  In the mammary gland, erbB3 and 
erbB4 cause a signaling cascade that activates STAT5a phosphorylation leading to 
lobuloalveolar development (Jones et al, 1999). Mice that lack HRG show decrease beta-
casein production, as well as reduced alveolar proliferation and differentiation (Li et al, 
2002).  This indicates that HRG, similar to PRL, is involved in the differentiation of 
mammary epithelial cells to milk-secreting lobuloalveolar structures (Jones et al, 1996). 
 
1.6.3 – Heregulin β-1 in Breast Cancer 
 
 Although HRG is involved in the normal development of the mammary glands 
during pregnancy, studies have also linked HRG to breast cancer progression.  HRG-β1 is 
linked to the STAT5a pathway, and can act as a mitogen, differentiation factor and 
transforming agent, raising questions on its effect in human breast cancer.  Studies have 
found that in cells over-expressing erbB2, HRG stimulation increases motility and 
invasion (DeCorte et al, 1994; Hijazi et al, 2000).  However, another paper reports that 
HRG-β1 causes the inhibition of proliferation and migration in highly metastatic breast 
cancer cells (Puricelli et al, 2002).  The same study also showed that HRG-β1 increased 
the amount of phosphotyrosine STAT5, indicating HRG acts through this pathway in 




MCF-7 and SKBr3, HRG-β1 causes an upregulation of MMP-9, which plays a role in 
invasion and angiogenesis of tumors (Yao et al, 2001). 
 
1.7 – Breast Cancer Cell Lines Used in this Study 
 
 
The ability to study cancer cells at the cellular or tissue level is beneficial because 
it allows for researchers to study mechanisms in greater detail, without having to worry 
about the difficulties of working with in vivo models.  Cell culture allows for an in depth 
study of molecular signaling pathways and gene regulation in human cells, without 
having to use an animal model.   
Cell lines derived from human breast tissue can be investigated for hormone and 
growth factor-mediated effects on RANK and RANKL gene expression.  This study will 
use two commonly used cell lines MCF-7 cells and MDA-MB-231 cells.  Both lines are 
human breast epithelial adenocarcinoma cells derived from a pleural effusion from a 
breast cancer patient.  The difference in these cell lines is that MDA-MB-231 cells are 
derived from a more progressed state of breast cancer than MCF-7 cells and therefore 
have slight differences in morphology and rate of proliferation.  MCF-7 cells retain 
several characteristics of differentiated breast epithelium and therefore in general contain 
more of the same cell receptors.  For instance, MCF-7 cells are known to contain high 
amounts of ERs (Brooks et al, 1973), while MDA-MB-231 cells are estrogen receptor-
negative.  MCF-7 cells also contain high levels of prolactin receptor (PRLR), 
transforming growth factor alpha-receptor (TGF-αR), insulin-like growth factor-1 
receptor (IGFR-1), progesterone receptor (PR), and some others.  MCF-7 cells also 




MDA-MB-231 cells have a fairly different receptor profile, only containing EGFR, TGF-
αR, IGFR-1 and low levels of erbB2 (HER2).  Differences in receptor profiling and cell 
morphology, will allow the two cell lines to react separately to various stimuli.  
 
1.8 – Research Objectives: 
 
1.8.1 – Hormonal Regulation of RANKL Gene Expression 
 
 
The overall objective of our research is to determine the mechanism of regulation 
of the expression of RANK/RANKL system in human breast cancer cell lines.  Although 
there is evidence that the RANK/RANKL system is involved in breast cancer progression 
and metastasis, it is not known under what circumstances (i.e. by which extracellular 
stimuli) the system is regulated.  We propose to determine the molecular mechanisms 
driving RANK and RANKL gene expression by studying mRNA levels in cancer cells 
stimulated with specific hormones and growth factors.  This research will focus on 
factors that are known to activate the Stat5a pathway, since this pathway is important in 
breast development and promotion of breast cancer and have been shown to regulate 
RANKL in mouse mammary epithelial cells (Srivastava et al, 2003).  The first objective 
of this research is to investigate the effects of the hormones prolactin and HRG-β1 and 
growth factor EGF, on the expression of RANKL mRNA in MCF-7 and MDA-MB-231 
cell lines.  Since induction of RANKL by hormones and growth factors has not been 
shown in human breast cancer, we hypothesize that stimulation by these hormones and 




After first testing the effects of PRL stimulation on RANKL in human breast 
cancers, the next focus was on other selected growth factors known to promote breast 
cancer progression via Stat5a.  These growth factors include heregulin (HRG-β1) and 
epidermal growth factor (EGF).   
 
1.8.2 – Modulation of Stat5a 
 
 
 The STAT5a pathway is involved in the regulation of many genes and has been 
linked to breast cancer progression.   RANKL is not normally expressed in breast 
epithelial cells or breast cancer cell lines, but induced expression has been linked to 
migration, proliferation and reduced apoptosis in mouse mammary epithelial cells.  If the 
specific growth factors or hormones induce RANKL expression, the next objective of this 
study is to determine whether it was regulated through the JAK2/STAT5a pathway.  
Using the selected growth factors or hormones that induce expression of RANKL, and a 
specific JAK inhibitor, studies can be used to examine the relationship between STAT5a 
activation and RANKL mRNA expression. This study will provide information that will 
add to the understanding of the regulation of RANKL in breast cancer and provide a link 









2 - Materials and Methods 
 
2.1 – Growth of Cell Lines 
 
 Human breast carcinoma cell lines, MCF-7’s (American Type Culture Collection 
(ATCC)) were maintained in Eagle’s Minimal Essential Media (EMEM) with Earle’s 
salts and 2mM L-glutamine (ATCC) supplemented with 10% fetal bovine serum (FBS) 
(Hyclone), 0.1% penicillin/streptomycin (p/s) (Hyclone) and 0.01mg/mL insulin (Sigma 
Aldrich).  These cells were incubated at 37oC with 5% CO2.  MDA-MB-231 cells 
(ATCC) were grown in L-15 Leibovitz’s media (Hyclone) with 2mM L-glutamine 
(Hyclone) supplemented with 10% FBS and 0.1% p/s.  They were grown at 37oC, in the 
absence of CO2.  Human intestinal epithelial, HT-29 cells were also purchased from 
ATCC.  These cells were maintained in RPMI-1640 medium (Hyclone) supplemented 
with 10% FBS and 0.1% p/s and incubated at 37oC at 5% CO2. 
 All cell lines were adherent cultures, grown in 75 cm2Corning cell culture flasks 
with 10mL of culture media.  Media was replaced every two days and cells were 
passaged after confluency reached 70-75%.  Cells were liberated using 1mL 0.5% 
Trypsin/EDTA (Hyclone).  First, media was aspirated and cells were washed three times 
with 1X PBS.  One mL of Trypsin/EDTA was added to the 75 cm2 flask and incubated 
for 2 minutes at 37oC.  Once cells were in suspension, they were rinsed with 10 mL of 
cell culture media and placed in a 50 mL Falcon tube.  Cells were spun at 1200 x g for 5 
minutes and the pellet was resuspended in 5 mL media.  One hundred μL were stained 
with a ½ dilution of trypan-blue (MP Biomedicals, Inc.) and counted using a 
hemocytometer.  After counting, one hundred thousand cells were added to each new 




106 cells diluted in 900μL EMEM were added to 100μL dimethyl-sulfoxide (DMSO) and 
300μL FBS.  Cells were frozen in cryovials (Fisher Scientific) and slow-frozen at -80oC 
in a Nalgene “Mr. Frosty” Cryo 1oC Freezing Container (Fisher Scientific) overnight and 
then transferred to liquid nitrogen. 
 
2.2 – Stimulation of MCF-7 and MDA-MB-231 cells with PRL, HRG-β1 and EGF 
 
 All hormones and growth factors were purchased from Sigma Aldrich.  PRL 
powder was reconstituted in 1mg/mL bovine serum albumin (BSA) (Invitrogen), 4 mM 
HCl solution (Sigma Aldrich) to a concentration of 50mg/mL.  The hormone was further 
diluted in serum-free EMEM media to a final concentration of 2.5mg/mL or 100nM, a 
concentration used in similar stimulation studies (Rui et al, 1994; Kirken et al, 1997).  
EGF was reconstituted in dH20 to a concentration of 100μM, and further diluted in 
serum-free EMEM media to a final concentration of 10nM.  HRG-β1 was resuspended in 
dH20 to a concentration of 5μg/mL and then further diluted to 20ng/mL in serum-free 
medium (Yao et al, 2001; Puricelli et al, 2002). 
For experimentation, cells were grown in 6-well plates with 2mL media in the 
appropriate conditions (as stated above).  Experiments began when cells were 80-90% 
confluent (approximately 500,000 cells per well).  Media was removed and replaced with 
1 mL serum-free media supplemented with the previously noted concentrations of PRL, 
EGF, or HRG-1.  RNA and protein samples were isolated at various time-points in order 
to identify the optimal length of stimulation for signal transduction, transcription and 
translation of genes.  Cells were stimulated for 15, 30 and 60 minute incubation periods at 
37oC at 5% CO2.  After stimulation, media was removed and cells were washed once with 




added to cells and cells were left to incubate for 24, 48, or 72 hours and RNA was 
isolated after this time.  Protein was isolated directly after stimulation, since only 
phosphorylation of STAT5a was being investigated.  
 
2.3 – Crystal Violet Assay 
 
 Proliferation of MCF-7 cells in the presence of PRL, EGF, and HRG-β1 was 
measured using a crystal violet assay.  In a 96-well plate, 5000 cells were added to 195μL 
of EMEM media containing 100nM PRL, 10nM EGF, 20ng/mL HRG-β1, or without 
growth factor or hormones.  Cells were incubated at 37oC in 5% CO2 for 2-5 days and the 
crystal violet assay was carried out every 24 hours.  Experiments were set up for 5 days, 
and all experiments were done in triplicate. 
 After each incubation period, the crystal violet assay was performed.  Media was 
removed from all wells by inverting the dish and gently blotting on absorbent pads.  
Wells were washed once with 200μL of 1X PBS and solution was removed by blotting on 
absorbent pads.  Fifty μL of 0.5% Crystal Violet Solution (Fisher Scientific) was added to 
each well and gently agitated for 10 minutes.  The dye was removed with reverse-osmosis 
water, until running clean and wells were left to dry for 30 minutes.  Cells were 
solubilized in 100μL DMSO solution by shaking for 10 minutes on low-speed.  
Absorbance of the solution was read at 570nm.  A standard curve of absorbance vs. cell 
number was generated using SigmaPlot to compare absorbance to estimate proliferation.  






2.4 - Detection of mRNA 
  
2.4.1 – RNA Isolation and cDNA Synthesis 
 
 Total RNA was isolated from MCF-7 and MDA-MB-231 cells using two 
methods: filtration and phenol-chloroform extraction.  RNA was isolated from 
approximately 5-10 million cells.  RNA was isolated 24 hours, 48 hours and 72 hours 
after stimulation with PRL, EGF and HRG-β1. 
The first method used the GenElute Mammalian RNA Isolation Kit (Sigma 
Aldrich).  Cells were isolated using 0.5% trypsin/EDTA and lysed in solution.  The cell 
lysate was filtered through a GenElute filtration column by spinning at 12, 000 x g for 
two minutes.  The filtered lysate was washed with 70% ethanol and this solution was 
filtered through the GenElute binding column by centrifugation.  The column was washed 
with Wash Solution I by centrifuging at 12, 000 x g for 15 seconds.  It was then washed 
twice with Wash Solution II, again centrifuging at 12, 000 x g for 15 seconds.  The RNA 
was then eluted using fifty μL of elution solution and centrifuging at 12, 000 x g for 1 
minute. 
The second method used TRIreagent also purchased from Sigma Aldrich.  Cells 
were lysed by adding 1 mL TriReagent to the wells and incubating for 2 minutes.  The 
lysate was then pipetted to a microfuge tube and 200 μL of chloroform was added.  The 
solution was incubated for 2-3 minutes at room temperature before being spun at 12, 000 
x g for 15 minutes at 4oC.  RNA was isolated from the upper aqueous layer by 
precipitation with 70% isopropyl alcohol.  The RNA was spun at 12, 000 x g for 10 
minutes and the pellet was washed with 75% ethanol.  RNA was resuspended in 20 μL 




One unit of RNAse inhibitor was added to all RNA solutions to prevent 
degradation.  Samples were then converted to cDNA or stored at -80oC.  RNA was 
reverse-transcribed to cDNA using Superscript II RT enzyme and oligo(dT)12-18 primers 
(Invitrogen).  Two μL of isolated RNA was combined with 25µg/mL oligo(dT)12-18 
primers and 0.5mM dNTPs.  The reaction was heated to 65oC in order for primers to 
anneal to the template mRNA strand.  The reaction was chilled on ice before 1X First 
Strand Buffer and 10mM DTT were added.  The cDNA synthesis was carried out at 42oC 
for fifty minutes using 200U Superscript II reverse transcriptase (RT).  The reverse 
transcriptase was inactivated by heating at 70oC for fifteen minutes.  cDNA samples were 
stored at -20oC. 
 
2.4.2 – Polymerase Chain Reaction (PCR) 
 
 GAPDH, RANK and RANKL transcripts were amplified from constructed cDNA 
using PCR.  All PCR primers were designed based on previous research and purchased 
from Integrated DNA Technologies (IDT).  PCR reactions were carried out using a 
Thermocycler Px2 (ThermoElectron) and GoTaq Hotstart Polymerase (Promega).  GoTaq 
was activated with an initial incubation of 95oC for 2 minutes. One microlitre of cDNA 
was used as template for each amplification reaction.   
Glyceraldehyde 3-phosphatase dehydrogenase (GAPDH3), a common 
housekeeping gene, was used as a genomic control for possible contamination of cDNA 
samples and as a positive PCR control.  Since the PCR amplification was not 
quantitative, this gene was only used as a control for genomic contamination. The 
following primers were used for amplification: 5’-ACCACAGTCCATGCCATCAC-3’ 




genomic DNA, and 451bp from cDNA.  These primers span an intron, which accounts 
for larger amplicon size from genomic DNA (Yan et al, 2006).  The reaction mixture 
included 120µM dNTPs, 10pmol primers, 4mM MgCl2 and 1.25U Taq.  Following the 
initial activation was thirty-five cycles of denaturing at 94oC for 30 seconds, primer 
annealing at 60oC for 30 seconds and extension at 72oC for 30 seconds.  Following these 
cycles, there was a final annealing reaction of 72oC for 10 minutes. 
 The following RANK primers were used to produce a 452bp fragment: 5’-
GGGAAAGCACTCACAGCTAATTTG-3’ (sense) and 
GCACTGGCTTAAACTGTCATTCTCC-3’ (antisense) and were described in Jones et al 
(2006).  This reaction was completed using a final concentration of 120µM dNTPs, 2mM 
MgCl, 10pmol primers, and 1U Taq.  The reaction was also started with an initial 
incubation at 95oC for 2 minutes, followed by thirty-five cycles of 94oC for 30 seconds, 
57oC for 30 seconds, and 72oC for 30 seconds, ending with a final extension at 72oC for 
10 minutes. 
 RANKL was amplified using the following primers: 5’-
ACTGGATCCGGATCAGGATG-3’ (sense) and 5’-AGCTGCGAAGGGGCACATGA-
3’ (anti-sense), amplifying a 386bp fragment. These primers were previously used to 
amplify RANKL in HT-29 cell lines (Vidal et al, 2003).  In this experiment, HT-29 cells 
were used as a control for RANKL expression.  The amplification of this fragment 
included final concentrations of 120µM dNTPs, 5pmol primers, 2mM MgCl2, and 1.25U 
Taq.  This reaction included thirty-five cycles of 94oC for 45 seconds, 60oC for 1 minute 
30 seconds, 72oC for 45 seconds, following the initial 95oC for 2 minutes.  The cycle was 





Table 1: Summary of the primers and conditions used to amplify each gene and the 
length products produced by PCR amplification 




























389 bp 556 bp 60oC 
 
 
2.4.3 – Electrophoresis and Sequencing of PCR Products 
 
 The size of each PCR product was determined by electrophoresis through a 1.5% 
agarose gel in 1X TAE buffer at 100V for approximately one hour for adequate 
separation.  Gels were stained with 0.5ng/mL ethidium bromide for twenty-five minutes 
and visualized under UV using a FluorChemTM SP (Alpha Innotech) gel-dock.  DNA 
fragments were excised from the agarose gel and purified using the PureLink Gel DNA 
Extraction Kit purchased from Invitrogen.  The agarose was dissolved by incubation in 
Gel Solublization Buffer at 50oC for fifteen minutes, mixing by inversion every three 
minutes.  The dissolved gel mixture was loaded onto a PureLinkTM Clean-up Spin 




column was then washed with Wash Buffer containing ethanol and centrifuged for 10 000 
x g for one minute.  After the flow-through liquid was removed, the column was dried by 
a final centrifugation at 13 000 x g for three minutes.  The DNA was eluted from the 
column by adding fifty microlitres Elution Buffer and incubating for one minute at room 
temperature and centrifuging at 13 000 x g for one minute.  The purified DNA was stored 
at -20oC. 
Purified PCR products were sent to Nanuq McGill University and Genome 
Quebec Innovation Center (Montreal, QC) for further purification and sequencing.  
Sequencing was completed with GAPDH3, RANK and RANKL primers described above. 
  
2.5 Protein Analysis  
 
2.5.1 – Protein Isolation 
 
 Protein was isolated from all cell lines using RIPA buffer containing 50mM Tris-
HCl (pH 7.4), 150mM sodium chloride (NaCl) (Sigma), 10mM 
ethylenediaminetetraacetic acid (EDTA), 0.1% Triton X-100 (Sigma), 1% 
NaDeoxycholate (Sigma), and 0.1% sodium dodecyl sulfate (SDS) (BioRad).  Cells were 
grown in a 6-well plate and grown to 80-100% confluency.  Cells were lysed with 100µL 
of RIPA buffer and kept on ice with gentle agitation for fifteen minutes.  The cell lysate 
was vortexed for one minute and kept on ice for ten minutes.  The DNA and cellular 
debris was sheared using a 22-gauge needle, then solutions were centrifuged at 13, 000 
rpm for twenty minutes at 4oC.  The supernatant containing the protein mixture was 
quantified using a Bradford Assay.  For the Bradford Assay, a standard curve was created 




with Bradford Reagent and incubated at room temperature for ten minutes.  Absorbance 
was read at 595nm using Synergy HT plate reader (Bio-Tek, Fisher).  Protein 
concentrations were calculated using the BSA standard curve.  Protein was stored at -
20oC in 30µg aliquots in 1X Laemmli buffer containing 30% glycerol (Sigma), 187.5mM 
Tris-HCl (pH 6.8), 6% SDS, 0.009% bromophenol blue (Sigma), and 5% beta-
mercaptoethanol (BioRad).  
 
2.5.2 - Western Blot Analysis 
 
Thirty micrograms of protein were separated on an acrylamide gel composed of 
an 8% resolving gel and 5% stacking gel.  The gel was run at 50V in Electrode buffer 
containing 14.4% glycine powder (MP Biomedicals, Inc) and 30.3% Tris-base (Sigma).  
Gels were run in the BioRad Mini-PROTEAN® Tetra Cell.  The samples were run at a 
constant voltage of 50V until the protein samples reached the resolving gel, when the 
voltage was increased to 100V until the samples reached the end of the gel.  Correct 
loading and running of the protein gels were determined by staining with Brilliant Blue G 
Concentrate (Sigma) for 30 minutes, followed by destaining with 50% methanol (Sigma), 
10% acetic acid (Sigma) solution with gentle agitation.  The destaining solution was 
changed several times, until the background stain was washed away and protein bands 
were clearly visible.  
 Protein was transferred from the acrylamide gel to a polyvinylidene fluoride 
(PVDF) membrane (BioRad) using the BioRad Mini Trans-Blot® Electrophoretic 
Transfer Cell.  The transfer was completed at 4oC overnight at 30V in transfer buffer 
containing 1X Electrode Buffer, 20% methanol and 0.01% SDS.  Transfer was confirmed 




fifteen minutes and washing the background with distilled water.  After transfer was 
confirmed, the membrane was washed with Wash Buffer, containing 1X TBS and 0.1% 
tween (Sigma), until the stain was removed. 
 
2.5.3 - Detection of STAT5a and phospho-STAT5a Protein 
 
 Antibodies for STAT5a, phospho-STAT5a and beta-actin were purchased from 
SantaCruz Biotechnology.  STAT5a (sc1081), p-STAT5a (sc-101806) and beta-actin (sc-
130657) are rabbit monoclonal antibodies that bind to 94kDa, 94kDa, and 43kDa 
peptides respectively. A secondary goat anti-rabbit IgG, horseradish peroxidase (HRP)-
conjugated antibody was used for detection of the primary antibody.  Antibody detection 
was accomplished using Enhanced Chemiluminescent (ECL) substrate (Pierce). 
To detect unphosphorylated STAT5a, the PVDF membrane containing transferred 
protein was incubated with 0.2µg/mL STAT5a (L-20) antibody in a Petri-dish for one 
hour at room temperature with gentle agitation.  To detect for phospho-STAT5a and beta-
actin, membranes were incubated overnight at 4oC with 0.1µg/mL p-STAT5a and beta-
actin (R-22) antibody. 
After incubation with the primary antibody, the membrane was washed three 
times with Wash Buffer in a Petri-dish, for ten minutes each.  The membrane was then 
incubated with 0.08µg/mL secondary antibodies for one hour at room temperature, and 
washed again for three consecutive washes.   Luminescence was completed using Thermo 
Scientific Pierce Enhanced Chemiluminescent (ECL) Western Blotting Substrate.  After 
wash solution was removed, equal quantities of Detection Solution #1 and #2 were 
poured over the membrane and left for five minutes at room temperature in the absence of 




autoradiography film (Fuji) for two minutes in an autoradiography cassette purchased 
from Fischer Scientific.  After exposure, the film was developed using the Kodak X-
OMAT 1000A Processor. 
 
2.6 – Inhibition Studies   
 
 Tyrphostin AG490 is a JAK2-specific inhibitor used to block the STAT5a 
pathway.  AG490 powder was purchased from Sigma Aldrich and reconstituted in DMSO 
to a concentration of 50mM and stored at -80oC in the absence of light.  AG490 was 
further diluted with PRL, EGF, or HRG-β1 in serum-free EMEM media.  Stimulation 
assays were carried out as described above with the presence of 50μM AG-490.  After 
stimulation for 15, 30 and 60 minutes, media containing stimulant and inhibitor was 
aspirated and cells were washed with 1X PBS.  Protein and RNA was isolated as 
described previously.  Expression of the GAPDH, RANK, and RANKL genes and 








3 - Results 
 
 3.1 - MCF-7 cells Express RANK, but not RANKL 
 
 RT-PCR was conducted using isolated RNA from MCF-7 cells.  PCR results in 
Figure 3 show that this cell line expresses RANK mRNA (452bp), while it does not 
express RANKL (327bp) under unstimulated conditions.  Human GAPDH3 expression 
was used as a control to indicate genomic contamination of RNA samples and as a 
positive control for RT-PCR procedures.  HT-29 cells were used as a positive control for 
RANKL expression.  PCR products were excised from the agarose gel, purified and sent 
for sequencing in order to further identify the products as RANK and RANKL.  The 
sequence information obtained from McGill University and Genome Quebec Innovation 
Center for the RANK and RANKL can be seen in Figure 4 A and 5A, respectively.  A 
BLAST search of the proposed RANK sequence (Figure 2B) shows that this product was 
in fact the human tumor necrosis factor receptor superfamily, member 11a (also known as 
RANK) mRNA.  The sequence alignment was highly similar, showing 98% identity, with 
0 gaps.  The BLAST search with the RANKL sequence isolated from HT-29 cells also 
confirmed the fact that the sequence was in fact human tumor necrosis factor (ligand) 
superfamily, member 11 (also known as RANKL) mRNA (Figure 3B).  This alignment 
showed 100% identity, with 0 gaps. Figure 6 shows PCR amplified GAPDH3 in genomic 
DNA isolated from MCF-7 and MDA-MB-231cells and shows two amplified bands, as 
compared to its detection in cDNA, showing only one band.  Primers were designed to 
span an intron in genomic DNA, so PCR would generate a larger band with genomic 









                       
 
 
Figure 3: RT-PCR products showing GAPDH (451bp), RANK (452bp) and the absence 







1    aagcactcac agctaatttg tggcactgga tcaatgaggc ttgtggccgc ctaagtggag 
61   ataaggagtc ctcaggtgac agttgtgtca gtacacacac ggcaaacttt ggtcagcagg 
121  gagcatgtga aggtgtctta ctgctgactc tggaggagaa gacatttcca gaagatatgt 
181  gctacccaga tcaaggtggt gtctgtcagg gcacatgtgt aggaggtggt ccctacgcac 
241  aaggcgaaga tgccaggatg ctctcatNNN NNagcaagac cgagatagag gaagacagct 









Figure 4: A -Sequence of purified RANK PCR fragment isolated from MCF-7 cells.  
Sequencing was done at the McGill University and Genome Quebec Innovation Center; 
B - BLASTn alignment of isolated RANK sequence (Query) with Homo sapiens tumor 











1    tggatccgga tcaggatgca acatactttg gggcttttaa agttcgagat atagattgag 
61   ccccagtttt tggagtgtta tgtatttcct ggatgtttgg aaacattttt taaaacaagc 
121  caagaaagat gtatataggt gtgtgagact actaagaggc atggccccaa cggtacacga 
181  ctcagtatcc atgctcttga ccttgtagag aacacgcgta tttacagcca gtgggagatg 
241  ttagactcat ggtgtgttac acaatggttt ttaaattttg taatgaattc ctagaattaa 










Figure 5: A - Sequence of purified RANK PCR fragment isolated from MCF-7 cells.  
Sequencing was done at the McGill University and Genome Quebec Innovation Center; 
B -Nucleuotide BLAST alignment of isolated RANKL (Query) with Homo sapiens tumor 























Figure 6: RT-PCR products of GAPDH3 showing the differences in amplicon size of 
genomic (555bp) and complementary (451bp) DNA isolated from MCF-7 and MDA-
MB-231 cell lines.  Lane 1: Blank (water control), 2: MDA-MB-231 genomic DNA, 3: 



















3.2 - RANKL Expression is Upregulated, while RANK Expression Diminishes in 
Response to PRL, EGF, and HRG-β1 in MCF-7 cells 
 
 Since RT-PCR of cDNA isolated from unstimulated MCF-7 cells demonstrated 
no RANKL expression, cells were stimulated with PRL, EGF, and HRG-β1 for varying 
amount of time in order to observe if RANKL expression could be induced.  MCF-7 cells 
were stimulated with growth factors or hormones for 15, 30 and 60 minutes, and RNA 
was isolated after 24, 48 and 72 hours for all treatments.  In cells stimulated with 100nM 
PRL, RANKL is induced in all stimulation and isolation time-points (Figure 7B).  
Looking at Figure 7C, there appears to be no cDNA amplification at the 60 minute 
stimulation were RNA was isolated at 72 hours. This particular time-point did not show 
GAPDH3 expression (Figure 7C).  RANK does not appear to be expressed in any PRL-
stimulated samples, except for detection after 15 minutes of exposure, where RNA was 
isolated at 24 or 48 hours (Figure 7A). 
 MCF-7 cells stimulated with 10nM EGF revealed RANKL expression in all 
samples and time-points, even after 60 minute stimulation and RNA isolation at 72 hours, 
although this band is very faint (Figure 8A).  These stimulated cells also showed no 
RANK expression in any samples (Figure 8B), while GAPDH3 was seen in all samples 
(Figure 8C). 
 HRG-β1-stimulated MCF-7 cells had RANKL expression in all cDNA samples 
except cells stimulated for 30 minutes, RNA isolated after 24 hours, and those stimulated 
for 60 minutes, with RNA isolated after 72 hours; however, since these samples did not 
express GAPDH3 they should not be included in this analysis of induced RANKL 
expression (Figure 9A and 9C).  No cDNA samples from MCF-7 cells stimulated with 




 Figure 10 shows that RANK was expressed in unstimulated MCF-7 cells and not 















Figure 7:RT –PCR showing RANK PCR product (A), the presence of RANKL (B) and 
GAPDH (C) expression in MCF-7 cells after 24 (P1), 48 (P2), and 72 (P3) hours after 
stimulation with 100 nM PRL for 15, 30 and 60 minutes. C(-) indicates a negative control 




















Figure 8:RT-PCR showing absence of RANK (A), the presence of RANKL (B) and 
GAPDH (C) expression in MCF-7 cells after 24 (E1), 48 (E2), and 72 (E3) hours after 
stimulation with 10 nM EGF for 15, 30 and 60 minutes. C(-) indicates a negative control 



















Figure 9:RT-PCR showing RANK PCR product (A) presence of RANKL (B) and 
GAPDH (C) expression in MCF-7 cells after 24 (H1), 48 (H2), and 72 (H3) hours after 
stimulation with 20 ng/mL HRG for 15, 30 and 60 minutes. C(-) indicates a negative 



























Figure 10: RT-PCR showing presence or absence of RANK in stimulated and 
unstimulated MCF-7 cells.  1 – cDNA created from MCF-7 cells stimulated with 100nM 




















3.3 - STAT-5a is Phosphorylated in Response to PRL, EGF and HRG-1 in MCF-7 
cells 
 
 After showing that RANKL can be upregulated by stimulation with PRL, EGF, 
and HRG-β1, protein isolation and western blot analysis was used to determine if these 
hormones and growth factors were acting through the STAT5a pathway to stimulate 
expression.  As shown in Figure 11 and 12, protein isolated from unstimulated MDA-
MB-231 and MCF-7 cells, respectively, show STAT5a protein expression (92kDa), but 
not p-STAT5a (94kDa). 
MCF-7 cells stimulated with PRL for 15 minutes showed little expression of p-
STAT5a, while those stimulated for 30 or 60 minutes displayed higher levels of p-
STAT5a expression (Figure 13A).  In protein isolated from all cells stimulated with PRL, 
STAT5a was no longer visible (Figure 13B).  At all time points of stimulation, cells 
grown in EGF showed p-STAT5a expression, as well as reduced levels of STAT5a 
(Figure 13A and B).  After growth with HRG-β1, cells show p-STAT5a, but STAT5a 































Figure 11:Western blot analysis of whole protein samples isolated from unstimulated 
MDA-MB-231 cells.  A – Membrane probed with Stat5a antibodies (94kDa); B – 























Figure 12: Western blot analysis of whole protein samples isolated from unstimulated 
MCF-7 cells.  A – Membrane probed with Stat5a antibodies (94kDa); B – Membrane 














Figure 13: Western blot analysis of whole protein isolated from MCF-7 cells after 
exposure to 100nM PRL (P), 10nM EGF (E) or 20 ng/mL HRG-β1 (H) for 15, 30 or 60 
minutes.  A – Membrane probed with Stat5a antibody (94kDa); B – Membrane probed 





3.4 - Inhibition of STAT5a Phosphorylation Causes Inhibition of RANKL 
Expression in MCF-7 cells treated with PRL and HRG-β1 
 
Cells were also incubated for 15 minutes with both AG490 inhibitor (to block 
STAT5 phosphorylation) in addition to hormones/growth factors and RNA was isolated 
after 24 hours to determine RANKL expression.  Cells incubated with both the inhibitor 
and PRL or HRG-β1 no longer showed RANKL expression, however cells incubated 
with EGF along with the inhibitor still exhibited detectable levels of RANKL mRNA.  
RANK was still not expressed after incubation with both the inhibitor and various 
hormones/growth factors. See Figure 14. 
 Tyrophostin AG490 is a JAK2 inhibitor, used here to inhibit the 
phosphorylation and activation of STAT-5a.  Figure 15A and B confirms the inhibitor 
activity by showing that cells incubated with the AG490 inhibitor and hormones/growth 






































Figure 14:RT-PCR of GAPDH3, RANK, and RANKL in MCF-7 cells stimulated with 
PRL, EGF, and HRG-β1 in the presence of 100 μM Tyrophostin AG490 inhibitor.  Lanes 
1, 4, 7 – GAPDH3 expression; Lanes 2, 5, 8 – RANK expression; Lanes 3, 6, 9 – RANKL 












































Figure 15: Western Blot Analysis of whole protein isolated from MCF-7 cells treated 
with AG490 inhibitor and PRL, EGF, or HRG-β1.  A – Stat5a expression (94kDa); B – 
Membrane probed with p-Stat5a (expected size – 94kDa) and β-actin (43kDa).  Lanes: 1 - 







3.5 - The Effects of PRL, EGF, and HRG-b1 on Proliferation in MCF-7 and MDA-
MB-231 cells 
 
 Proliferation of MDA-MB-231 and MCF-7 cells untreated, and treated with PRL, 
EGF and HRG-β1, was determined using crystal violet staining and reading absorbance 
at 570nm.  Standard curves were created to relate absorbance values to actual cell 
number.  A linear standard curve was created for each cell line with cell numbers ranging 
from 5000 to 30 000 cells.  The standard curve for MDA-MB-231 cells produced a linear 
relation of y = 4.01913*10-5x + 0.1446 (Figure 16), while the curve for MCF-7 cells 
produced a relation of y = 7.94945*10-5x + 0.2233 (Figure 17), where x represents the 
number of cells and y represents the absorbance at 570nm. 
 In MDA-MB-341 cells, there was no significant difference between the numbers 
of cells after 72 hours for untreated and cells treated with PRL, HRG-β1 and EGF (Figure 
18, 19, 20).  After 96 hours, cells stimulated with 100nM PRL did show a significant 
increase in cell number compared to the control sample, p=0.009542808 (Figure 18).  In 
MCF-7 cells, there was no significant difference between the numbers of cells from 0 to 
120 hours for untreated cells and for those treated with PRL, EGF, or HRG-β1 (Figure 









Figure 16: Standard curve relating the number of MDA-MB-231 cells to the absorbance 
(570nm) read from the crystal violet assay (n=5). 
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Figure 17: Standard curve relating the number of MCF-7 cells to the absorbance 
(570nm) read from the crystal violet assay (n=5) 
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Figure 18: Proliferation of MDA-MB-231 cells over a span of four days (96 hours) in 
untreated control cells as compared to cells treated with 100nM PRL ; * 
indicates a p-value < 0.05; (n= 5) 
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Figure 19: Proliferation of MDA-MB-231 cells over a span of four days (96 hours) in 
untreated control cells  as compared to cells treated with 10nM EGF ; (n= 5) 
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Figure 20: Proliferation of MDA-MB-231 cells over a span of four days (96 hours) in 



























Figure 21: Proliferation of MCF-7 cells over a span of four days (96 hours) in untreated 
control cells as compared to cells treated with 100nM PRL ; (n= 5) 
  
Time (hours)




















Figure 22: Proliferation of MCF-7 cells over a span of four days (96 hours) in untreated 
control cells as compared to cells treated with 10nM EGF ; (n= 5) 
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Figure 23: Proliferation of MCF-7 cells over a span of four days (96 hours) in untreated 
control cells  as compared to cells treated with 20ng/mL HRG ; (n= 5) 
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4 - Discussion 
 
4. 1 - RANK and RANKL Expression in Human Breast Cancer Cells 
 
In normal breast epithelial cells, RANK is constitutively expressed throughout 
development, while RANKL is only expressed during the stages of pregnancy and 
lactation.  It is at this point that cells are rapidly dividing and forming lobuloalveolar 
structures. Previous studies have shown that RANK, but not RANKL mRNA is expressed 
in many human breast carcinoma cells.  One study in particular indicated that although 
RANK is expressed in normal breast epithelial cells, as well as tumor cells invading 
bone, RANKL is only expressed in metastatic cells (Bhatia et al, 2005).  Another study 
showed by quantitative RT-PCR, that RANKL is weakly expressed in tissues isolated 
from human breast tumors (Reinholz et al, 2002).  
As shown in Figure 3, MCF-7 cells grown in their regular culture medium 
expressed RANK mRNA and but not RANKL mRNA, consistent with previous research.  
Purified RT-PCR amplicon were sequenced and confirmed identity of human RANK and 
RANKL (Figure 4 and 5).  
 
4.2 – Effects of PRL on MCF-7 and MDA-MB-231 cells  
 
4.2.1 - PRL Induces RANKL Expression through the JAK2-STAT5a Pathway in MCF-7 
cells 
 
 Although RANKL is not normally expressed in MCF-7 or MDA-MB-231 cells, 
when MCF-7 cells are treated with 100nM PRL, RANKL mRNA expression is induced 
(see Figure 7B).  RANKL mRNA was detectable after 15, 30 and 60 minutes of 




cDNA, as the RT-PCR control, GAPDH3, was not amplified (see Figure 7C).  This may 
have been a problem with RNA isolation, or with the synthesis of complementary DNA.  
However, it is clear that RANKL was upregulated with the addition of PRL to the culture 
media.  This process appears to be regulated through the Stat5a pathway, as addition of 
PRL to the growth culture media induced STAT5a to become phosphorylated (see Figure 
13).  AG490 is a specific inhibitor of JAK2 phosphorylation, thereby inhibiting the 
subsequent phosphorylation of STAT5a. When STAT5a phosphorylation is blocked with 
a JAK2 inhibitor, PRL was no longer seen to induce RANKL expression, therefore 
linking the expression of RANKL directly to phosphorylation of STAT5a (see Figure 
14).  Activation of the STAT5a by PRL is a well-characterized event in mammary 
epithelial cells (Srivastava et al, 2003) and human breast cells.  Our work is consistent 
with Srivastava et al (2003), which showed that RANKL could be induced by PRL 
through the STAT5a pathway in mouse mammary epithelial cells.  In human breast 
cancer cells, including both MCF-7 and MDA-MB-231 cells, PRL was also able to 
activate STAT5a through JAK2 phosphorylation.  Our research shows that PRL induced 
activation of JAK2 and phosphorylation of STAT5a and that this activation is responsible 
for the transcriptional regulation of the RANKL gene.  
 
4.2.2 - PRL stimulates proliferation in MDA-MB-231 cells, but not MCF-7 cells  
 
 Prolactin acts to stimulate proliferation and differentiation of terminal end buds 
into milk-secreting lobuloalveolar structures.  PRL is distinguished as a mitogen and is 
known to activate proliferation in murine mammary and human breast epithelial cells. 
Therefore, it was expected that human breast cancer cells expressing a receptor to PRL 




100nM PRL, only MDA-MB-231 cells showed a significant increase in cell number 
when compared to the control study. This finding is interesting given the fact that MDA-
MB-231 cells do not actually possess the PRLR; therefore PRL is stimulating 
proliferation through another unknown mechanism.  
On the other hand, MCF-7 cells do possess the PRLR and in fact, one study 
conducted by Ginsberg and Vanderhaar (1995) revealed that PRL exposure causes 
proliferation in MCF-7 human breast cancer cells.  This same study showed that MCF-7 
cells might actually synthesize and secrete PRL in preconditioned media.  Our 
experiment showed that after all four days, MCF-7 cells did not show a significant 
difference in cell number with PRL (see Figure 21), however more replicates of this 
experiment are required before further conclusions can be drawn. 
Since the effects of PRL on cell number was only seen after the fourth day in 
MDA-MB-231 cells, it is likely that further proliferation studies with longer PRL 
exposure, more time points taken and even more alternative methodologies may reveal 
different results in both cell lines.  
 
4.3 – The Effects of EGF on MCF-7 and MDA-MB-231 cells 
 
4.3.1 - EGF Induces RANKL Expression through the JAK2-STAT5a and other pathways 
in MCF-7 cells 
 
 EGF acts through the EGFR to induce signals through a variety of signal 
transduction pathways.  In this study, stimulation of MCF-7 cells with 10nM EGF 
showed an induction in RANKL transcription after only 15 minutes of stimulation time 
(Figure 8B).  In a study by Biswas et al (2000), human breast cancer cell lines treated 




increase in RANKL transcription, it is possible that the activation of NF-κB in human 
cancer cells was due to the activation of the RANK-RANKL pathway.  
In unstimulated MCF-7 cell lines, there was no p-STAT5a present (see Figure 
12), however addition of EGF to the culture medium not only induced cells to expressed 
RANKL, but p-STAT5a was also isolated from whole protein lysates.  To connect the 
STAT5a activation to RANKL expression, JAK2 activity was inhibited with AG490.  In 
this case, RANKL was still being transcribed in MCF-7 cells stimulated with EGF.  This 
indicates that although EGF may be activating the JAK2-STAT5a pathway to induce 
STAT5a phosphorylation, there must be one or more pathways also activated which are 
causing RANKL induction.  EGF not only activates STAT5a through JAK-activation, but 
it is also known to activate a variety of other pathways, including the Ras/MAPK 
pathway (Scaltriti and Baselga, 2006), PLC-γ (Wahl et al, 1990), and PI3K (Bjorge et al, 
1990).  Although JAK2 phosphorylation is required for STAT5a activation in most cases, 
EGFR can also directly phosphorylate STAT proteins, only requiring JAK2 for maximal 
activation.  One study actually showed that EGFR activates STAT1, 3 and 5 via Src in 
human breast cancer cells (Olayioye et al, 1999).  Olayioye et al (1999) also indicated 
that EGFR-Src activation of STAT5a cause phosphorylation of tyrosine residues other 
thanY694, possibly allowing these phosphorylated STAT5a proteins to effect different 
downstream targets.  This means that AG490 inhibition may not have been sufficient to 
obstruct all STAT5 activation by EGF.  Our studies indicate that after incubation with the 
AG490 JAK2 inhibitor, STAT5a Y694 phosphorylation as detected by the specific sc-
101806phospho-STAT5a (Tyr694) antibody is diminished. Since STAT5a 




through an alternative pathway to induce RANKL expression. Further studies in which 
these pathways can be specifically inhibited will have to be conducted in order to 
determine the exact mechanisms responsible for the EGF-regulation of RANKL 
transcription in breast cancer cells. 
 
4.3.2 – EGF does not show stimulation of proliferation in human breast cancer cells 
 
EGF is responsible for the proliferation of ductal epithelial cells in mammary 
gland development (Wiesen et al, 1999).  In breast cancer, there is a strong correlation 
between the amount of EGFR and cell proliferation (Marti et al, 1991).  Therefore, it was 
expected that EGF would increase the rate of proliferation in human breast cancer cells in 
this study.  Since MDA-MB-231 cells contain higher levels of EGFR, the effect in these 
cells would be expected to be greater than in MCF-7 cells.  However, in the experiment 
shown, EGF did not cause a significant increase in proliferation (see Figure 22).  This is 
in contrast to a previous study indicated that stimulation of MCF-7 cells with EGF had a 
significant increase in proliferation with EGF concentrations as low as 0.01ng/mL 
(Osborne et al, 1980).  
 
  
4.4 – The Effects of HRG-β1 on MCF-7 and MDA-MB-231 cells 
 
4.4.1 - HRG-β1 Induces RANKL Expression through the JAK2-STAT5a Pathway in 
MCF-7 cells 
 
 Similar to PRL and EGF, HRG-β1 is also involved in mammary gland 
development during pregnancy and is responsible for the formation of lobuloalveolar 
structures (Yang et al, 1990).  HRG binds to erbB3 and erbB4 causing activation of 




that HRG-β1 would mediate expression of the RANKL gene.  In this study, HRG-β1 
caused MCF-7 cells to express RANKL mRNA.  Expression of RANKL mRNA was 
seen after only fifteen minutes of exposure to 20ng/mL HRG-β1 (see Figure 9B).  This 
means that HRG is upregulating the expression of RANKL mRNA expression in MCF-7 
human breast cancer cells. 
 When JAK2 phosphorylation was inhibited using AG490 in HRG-stimulated 
MCF-7 cells, RANKL mRNA expression was no longer seen (see Figure 14).  This 
indicates that similar to PRL, HRG-β1 causes JAK2 phosphorylation, which causes 
phosphorylation and activation of STAT5a and subsequently promotion of the RANKL 
gene.  Therefore this inhibition study proves our hypothesis that HRG stimulates RANKL 
mRNA expression through activation of the JAK2-STAT5a pathway in MCF-7 human 
breast cancer cells. 
 
4.4.2 - HRG-β1 stimulation does not result in increased proliferation of human breast 
cancer cells 
 In this study, HRG-1 did not induce proliferation in MDA-MB-231 (see Figure 
20) or MCF-7 (see Figure 23) human breast cancer cell lines.  Treated cells displayed cell 
numbers that were not statistically different than untreated cells, throughout the entire 
four-day period.  Although MCF-7 cells contain both the erbB3 and erbB4 receptors, 
MDA-MB-231 cells only contain EGFR and low levels of erbB2 (Ferger et al, 1998), 
which do not convey the HRG-response.  Therefore, if we were only assuming that HRG 
is only binding erbB3 and erbB4, we would only expect MCF-7 cells and not MDA-MB-




Previous studies have shown HRG to increase cell proliferation in HC11 
mammary epithelial cells (Marte et al, 1995) and in vivo, creating ductal branching in 
mice (Jones et al, 1996).  Proliferation was also increased through HRG stimulation in 
MCF-7 (Lewis et al, 1996; Hutcheson et al, 2007), T47D and many other human breast 
cancer cell lines (Lewis et al, 1996).  Studies on invasive, metastatic breast cancers show 
conflicting results, indicating a decrease in proliferation due to HRG-stimulation.  
Puricelli et al (2002) and Xu et al (1992) have shown that HRG can actually inhibit 
proliferation in metastatic mammary tumor cells and breast cancer cells, respectively. 
 
4.5 - RANK Expression is diminished in MCF-7 cells After Addition of PRL, EGF 
and HRG-β1 
 
Although this study was intended to determine the regulation of RANKL gene 
expression, we have also determined that the addition of PRL, EGF and HRG-1 not only 
induces RANKL expression, each also caused a decrease in RANK mRNA expression.  
In all treatments, RANK expression was diminished and was not revived after addition of 
the AG490 inhibitor (see Figure 14).  This indicates that the JAK2 activation of the 
STAT5a pathway is not the reason for this change in expression.  No previous research 
has studied the effects of these factors on RANK mRNA expression; therefore it is 
unclear what specifically may be causing this response.  As shown in Figure 10, RT-PCR 
of RANK cDNA from stimulated and unstimulated cells show this effect to be specific to 
the addition of hormones and growth factors to the media.  Previous studies has shown 
RANK is expressed in normal and cancerous breast cells.  Srivastava et al (2003) showed 
that RANKL was upregulated by PRL in mammary epithelial cells, but RANK 




PRL, EGF, or HRG-1 on the expression of RANK mRNA.  It is possible that the 
compounds are acting through alternative pathways to regulate the expression of this 
gene. 
 
4.7 - Therapeutic Implications 
Many studies have recognized thea link between breast and bone metastases to be 
the RANK-RANKL pathway.  Since stimulation of the RANK-RANKL pathway is 
believed to cause an increase in metastasis of breast cancer to bone, clinical studies are 
currently underway to examine  how this pathway can be regulated to control the spread 
of cancer.  Under normal physiology, OPG acts to inhibit the RANK-RANKLpathway in 
osteoclasts, thereby regulating the process of bone remodeling. Given that OPG acts in 
this way, it is hypothesized that this molecule would limit breast-to-bone metastases.  In 
fact, studies show that mice treated with recombinant OPG show decreased osteolytic 
destruction and tumor burden in bone (Morony et al, 2001).  Recombinant OPG has been 
used in clinical trials (Body et al, 2003) and was shown to suppress bone resorption; 
however, more trials are needed to determine the effects on metastases and long term 
implications.  Other inhibitory methods, including neutralizing antibodies specific for 
RANK, are being investigated.  Our studies attempt to determine the regulation of the 







4.8 - Future Directions 
 
In this study RANKL mRNA transcripts are used as an indication of RANKL 
expression.  Ideally protein expression would also be studied in order to obtain an 
accurate impression of RANKL expression.  However, currently there has been little 
success with antibodies designed to bind RANK or RANKL, likely because these 
proteins are involved in T-cell activation and immune function.  Although some 
antibodies are available there has been limited success.  Identifying the induction of 
RANKL mRNA still allows us to identify how transcription of the gene is regulated.  In 
order to determine if the RANKL protein is actually upregulated, an option for future 
research would involve directly tagging the RANK receptor.  If the RANK protein itself 
is manufactured with a fluorescent tag, it is possible to get an indication of RANKL 
protein expression, by looking at protein-protein interactions on the cell surface.  
The effects of hormones and growth factors can also be examined using cells 
over-expressing the RANK receptor.  
Proliferation assays did not show significant differences in cell number between 
treated and untreated samples for MCF-7 cells, and the only increase in growth was seen 
with PRL stimulation in MDA-MB-231 cell lines.  Since previous research contradicts 
our results, further experiments will need to be conducted to prove validity.  Taking more 
time-points for results, and increasing the length of the study may give a more accuracy 
to our results.  It would also be beneficial to try different methods of measuring cell 
proliferation in order to confirm our results.  Crystal violet binds DNA and thereby 
measures the relative number of cells; therefore, troubles may arise when binucleated 




that measure metabolic activity, for example, WST-1, MTT and XTT assays.  Other 
available methods include measuring the incorporation of radioactive molecules in DNA 
synthesis and measuring fluorescence.  An example of this type of method includes 5-
bromo-2-deoxy-uridine labeling.  Therefore, given the wide variety of proliferation 
assays available, it would be beneficial to explore various methods to confirm the results 
of this study.   
Although these experiments indicated that EGF could activate phosphorylation of 
STAT5a, it was not solely this pathway that was involved in RANKL induction.  In order 
to elucidate the mechanism of RANKL expression, further studies will need to be done 
targeting other pathways activated by EGF.  
Lastly, hormone and growth factor effects on RANK and RANKL mRNA 
expression could be further investigated using more quantitative methods such as real-
time PCR.  Our study only focuses on induction or complete removal of gene expression, 
therefore it would be beneficial to quantify these results.  As mentioned, protein studies 
would also give a better indication of RANK and RANKL expression within the cell. 
This study gives insight to the regulation of RANK and RANKL expression in 
human breast cancer, providing the foundation for understanding the mechanism of 




5 – Conclusion 
 
 
This study was conducted to determine the regulation of RANKL mRNA 
expression in human breast cancer cell lines.  Both RANKL and STAT5a play an 
important role in development of normal mammary tissue, and we attempted to establish 
this same link in breast cancer cell lines using growth factors and hormones known to 
activate STAT5a.  Three important STAT5a activators were used: PRL, EGF and HRG-1, 
all which have important roles in lobuloalveolar formation and are also implicated in 
breast cancer progression.  We confirmed that both MDA-MB-231 and MCF-7 cells 
express RANK mRNA, and neither express RANKL under normal culture conditions.  In 
MCF-7 human breast cancer cells, all treatments were able to induce RANKL expression.  
Both PRL and HRG-1 induced RANKL mRNA expression through activation of the 
STAT5a pathway, while it appears EGF induced expression through an alternative 
pathway.  Intriguingly, RANK expression appears to be downregulated by these same 
factors and further studies may elucidate this mechanism.  Results are too preliminary to 
conclude on the ability of these hormones and growth factors to promote proliferation in 
these cell lines.   
Overall this investigation provides evidence for STAT5a-induced RANKL 
mRNA expression in human breast cancer.  The study indicates that several factors may 
be regulating RANK and RANKL expression in breast cancer cells, which may lead to 
further cancer progression and links to metastasis to bone.  This is the first study that 




be conducted to determine the further mechanisms of RANKL induction, its role in breast 
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